新型抗肿瘤药物依曼替尼布  

A novel antineoplastic agents: imatinib

作　　者：梁爽[1] 刘超美[1] 

机构地区：[1]中国人民解放军第二军医大学药学院有机化学教研室,上海200433

出　　处：《中国新药与临床杂志》2002年第9期567-569,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：依曼替尼布是一种新型的 2 苯胺基嘧啶类酪氨酸激酶抑制药 ,用于α 干扰素治疗失败后的慢性髓样白血病 (CML)慢性期病人、加速期病人、急变期病人的治疗。Imatinib is a novel tyrosine protein kinases inhibitor of the 2-phenylaminopyrimidine derivative. It is indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. The clinical studies shows that imatinib is very effective in hematologic response and major cytogenetic response in CML patients.

关 键 词：依曼替尼布 抗肿瘤药 慢性髓样白血病 治疗 

分 类 号：R979.1[医药卫生—药品] R733.72[医药卫生—药学]